Adjunctive diagnostic tool for histopathological classification of congenital mesoblastic nephroma based in molecular genetic findings
p-Mek1/2 and p-Erk1/2 immunoreactivity may be useful markers for EGFR-ITDs. Thus, MEK1/2 inhibitors possess the potential to be used as a targeted therapy for CMN with EGFR-ITDs.
Authors
- Takeshi Iwasaki (ORCID: https://orcid.org/0000-0001-5277-2932)
- Kenichi Kohashi (ORCID: https://orcid.org/0000-0002-2358-7452)
- Mikiko Hashisako (ORCID: https://orcid.org/0000-0001-5245-7342)
- Hiroshi Hamada (ORCID: https://orcid.org/0000-0002-7196-5948)
- Yoshinao Oda (ORCID: https://orcid.org/0000-0001-9636-1182)
- Naonori Kawakubo (ORCID: https://orcid.org/0000-0003-0010-4902)
- Masahiro Fukuhara (ORCID: https://orcid.org/0000-0002-4162-9361)
- Yuko Hino (ORCID: https://orcid.org/0000-0003-0265-4350)
- Tatsuro Tajiri
- Amane Kamouchi
Institutions
- Kyushu University (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s00432-025-06116-x
- Citations
- 1
- Primary Topic
- Renal and related cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.81